Xeris Biopharma (XERS) Competitors $3.49 +0.08 (+2.35%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends XERS vs. AKRO, TARS, AMPH, IRON, CGON, HRMY, GLPG, XNCR, EVO, and ARQTShould you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Akero Therapeutics (AKRO), Tarsus Pharmaceuticals (TARS), Amphastar Pharmaceuticals (AMPH), Disc Medicine (IRON), CG Oncology (CGON), Harmony Biosciences (HRMY), Galapagos (GLPG), Xencor (XNCR), Evotec (EVO), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. Xeris Biopharma vs. Akero Therapeutics Tarsus Pharmaceuticals Amphastar Pharmaceuticals Disc Medicine CG Oncology Harmony Biosciences Galapagos Xencor Evotec Arcutis Biotherapeutics Akero Therapeutics (NASDAQ:AKRO) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership. Do analysts rate AKRO or XERS? Akero Therapeutics currently has a consensus target price of $46.83, suggesting a potential upside of 59.62%. Xeris Biopharma has a consensus target price of $4.87, suggesting a potential upside of 39.45%. Given Akero Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Akero Therapeutics is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has higher earnings and valuation, AKRO or XERS? Xeris Biopharma has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$151.76M-$3.75-7.82Xeris Biopharma$187.36M2.78-$62.26M-$0.45-7.76 Does the media refer more to AKRO or XERS? In the previous week, Akero Therapeutics had 9 more articles in the media than Xeris Biopharma. MarketBeat recorded 10 mentions for Akero Therapeutics and 1 mentions for Xeris Biopharma. Akero Therapeutics' average media sentiment score of 0.75 beat Xeris Biopharma's score of 0.67 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AKRO or XERS more profitable? Akero Therapeutics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Akero Therapeutics' return on equity of -32.46% beat Xeris Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -32.46% -29.83% Xeris Biopharma -33.69%-16,662.63%-17.38% Which has more risk & volatility, AKRO or XERS? Akero Therapeutics has a beta of -0.23, indicating that its stock price is 123% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Do insiders & institutionals have more ownership in AKRO or XERS? 42.8% of Xeris Biopharma shares are owned by institutional investors. 7.9% of Akero Therapeutics shares are owned by insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer AKRO or XERS? Xeris Biopharma received 35 more outperform votes than Akero Therapeutics when rated by MarketBeat users. Likewise, 69.76% of users gave Xeris Biopharma an outperform vote while only 63.53% of users gave Akero Therapeutics an outperform vote. CompanyUnderperformOutperformAkero TherapeuticsOutperform Votes10863.53% Underperform Votes6236.47% Xeris BiopharmaOutperform Votes14369.76% Underperform Votes6230.24% SummaryXeris Biopharma beats Akero Therapeutics on 9 of the 17 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XERS vs. The Competition Export to ExcelMetricXeris BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$508.37M$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E Ratio-7.7610.5089.8217.18Price / Sales2.78195.801,116.21116.95Price / CashN/A57.1642.8937.86Price / Book-69.805.094.784.78Net Income-$62.26M$151.83M$120.23M$225.60M7 Day Performance6.40%-2.13%-1.92%-1.23%1 Month Performance14.80%-3.10%11.49%3.36%1 Year Performance66.19%11.54%30.57%16.60% Xeris Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XERSXeris Biopharma3.6033 of 5 stars$3.49+2.3%$4.87+39.4%+73.6%$508.37M$187.36M-7.76290News CoveragePositive NewsAKROAkero Therapeutics4.0824 of 5 stars$29.00+0.4%$46.83+61.5%+36.1%$2.02BN/A-7.7030Insider TradeTARSTarsus Pharmaceuticals0.3236 of 5 stars$51.52-1.9%$54.20+5.2%+164.4%$1.97B$17.45M-13.7850Positive NewsAMPHAmphastar Pharmaceuticals4.8626 of 5 stars$40.91-3.1%$60.33+47.5%-33.1%$1.97B$644.40M14.081,761IRONDisc Medicine3.4713 of 5 stars$65.58+1.1%$87.50+33.4%+13.2%$1.95BN/A-16.3078Insider TradeCGONCG Oncology2.1551 of 5 stars$28.43-1.1%$63.88+124.7%N/A$1.92B$684,000.000.0061Insider TradeHRMYHarmony Biosciences4.7827 of 5 stars$32.81+1.3%$47.00+43.2%+7.0%$1.87B$681.88M15.35200Analyst ForecastAnalyst RevisionGLPGGalapagos0.6163 of 5 stars$27.00+0.7%$30.75+13.9%-31.4%$1.78B$260.09M0.001,123XNCRXencor4.3204 of 5 stars$25.17+4.7%$36.56+45.2%+18.4%$1.76B$168.34M-7.51280EVOEvotec2.387 of 5 stars$4.68+4.2%$5.93+26.8%-60.5%$1.66B$777.05M0.005,061Positive NewsARQTArcutis Biotherapeutics0.8599 of 5 stars$13.31+4.9%$15.50+16.5%+478.8%$1.56B$138.71M-7.58150Options VolumePositive News Related Companies and Tools Related Companies AKRO Alternatives TARS Alternatives AMPH Alternatives IRON Alternatives CGON Alternatives HRMY Alternatives GLPG Alternatives XNCR Alternatives EVO Alternatives ARQT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XERS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
